Engineering T cell therapies for cancer and chronic diseases | @Columbia Institute for Cell Engineering and Therapy (CICET)
New York, NY
Joined April 2017
- Tweets484
- Following264
- Followers1.1K
- Likes1.7K
Max Mamonkin retweeted
IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer).
nature.com/articles/s41586-0…
Max Mamonkin retweeted
A cell intrinsic NKG2A/C switch receptor to overcome the critical HLA-E checkpoint. Fun collaboration with the Michel Sadelain lab. Michelle Sætersmoen, Ivan Kotchetkov, @LambertoTR @CoE_PRIMA @UniOslo_MED @Oslounivsykehus @CIM_Sweden
Online Now: Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor dlvr.it/TFV5VC
Max Mamonkin retweeted
I am very pleased to announce the work I did as a graduate student in the labs of Crystal Mackall and Everett Meyer has been published in Nature Communications, open access! nature.com/articles/s41467-0…
Max Mamonkin retweeted
Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center.
➡️columbiamed.link/3zCR9iI
ALT Columbia welcomes Michel Sadelain, MD, PhD, Director of the Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center.
Max Mamonkin retweeted
Recruiting faculty to the Dept of Molecular and Cellular Biology at Baylor College of Medicine in Houston, TX! Recruiting broadly in cancer and cell biology. Submit by October 1, 2024, for full review. #cellbio @BCMhouston
bcm.edu/departments/molecula…
jobs.sciencecareers.org/job/…
Max Mamonkin retweeted
Preprint alert 🚨
Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐
Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells
biorxiv.org/content/10.1101/…
🧵👇
Max Mamonkin retweeted
My department (MIT Biological Engineering) is hiring at the Assistant Professor level! We are looking for someone in immunology/immunotherapy/immune engineering, broadly defined. be.mit.edu/about/open-facult…
Great step forward in humanized mouse models. Using iPSC-derived CD34+ iHSC which engraft and produce human multi-lineage progeny in immunodeficient NBSGW mice
nature.com/articles/s41587-0…
An interesting POC of T cell therapy in CNS injury models: autoreactive MOG-specific T cells infiltrate the lesion and suppress tissue damage, counter-intuitively in part via IFNg secretion. But you have to act fast.
nature.com/articles/s41586-0…
Excellent results with autologous CD7-PEBL CART in T-ALL from Singapore and Rome nature.com/articles/s41591-0…
Max Mamonkin retweeted
The genomic basis of childhood T-lineage acute lymphoblastic leukaemia | Nature nature.com/articles/s41586-0…
T cells express a ton of CD5, so why CD5 CAR T cells don't kill each other? Turns out, they completely degrade CD5 protein and thus evade fratricide. Unique mechanism unveiled in a mechanistic study - and PhD thesis work - by Royce Ma:
cell.com/cell-reports-medici…
Max Mamonkin retweeted
Congrats to the now Dr. @_ruchipatel
for the publication of her PhD thesis in @SciImmunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. @PennMedicine @RuellaLab science.org/doi/10.1126/scii… – at Philadelphia, PA
Max Mamonkin retweeted
Are all hybrid antigen receptors as easy to design as CARs? Definitely not! doi.org/10.1158/2159-8290.CD… (1/4)
Max Mamonkin retweeted
Comprehensive thread highlighting our most recent work now out in @CellStemCell describing a novel approach to increase persistence of allogeneic cell therapy products. Work led by amazing @QuirinHammer and @KarloPerica. @CoE_PRIMA, @Oslounivsykehus @UniOslo_MED @karolinskainst
Happy to share the final work from my post-doc with @MalmbergLab published in @CellStemCell today cell.com/cell-stem-cell/full…
extensive 15-post-🧵 below
Limiting institutional overhead on NIH grants?
Paragraph tucked into House NIH funding bill to limit indirects makes research $ go further and attacks administrative bloat at wealthy colleges. Proposal caps indirects at 30% rather than reimbursing at a school's actual overhead rate. Current policy encourages wasteful spending at universities; this bill creates a powerful incentive to control costs.
via @stuartbuck1
The answer is NO. Here's a patient with neuroblastoma who was treated 18 years ago with GD2.CAR T cells at Baylor @CAGTHouston and still remains in remission. We need more of these stories.
researchsquare.com/article/r…
Matt Rea was treated with CD19 CART cells back in 2010 at Baylor @CAGTHouston and has been cancer-free since then, for 14 years. The CAR-T were made from his twin brother. Is he the longest surviving CAR-T patient?
blogs.bcm.edu/2024/06/04/fol…
Matt Rea was treated with CD19 CART cells back in 2010 at Baylor @CAGTHouston and has been cancer-free since then, for 14 years. The CAR-T were made from his twin brother. Is he the longest surviving CAR-T patient?
blogs.bcm.edu/2024/06/04/fol…
Like many disruptive technologies, engineered T-cell therapies follow the Gartner hype cycle. We are approaching the second upward slope.
Max Mamonkin retweeted
🚀 Join Our Team at Baylor College of Medicine! 🧬
We’re looking for passionate technician to join our lab at @CAGTHouston. Help us develop innovative and accessible cell therapies for cancer and autoimmunity using genome editing.
Pls RT 🙏
jobs.bcm.edu/job/Research-Te…